Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078195 · ClinicalTrials.gov registry record · Phase 2
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
A Phase 2 study of Allergy and Hypersensitivity, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 3
- Study locations
NCT00078195 is a Phase 2 study of Allergy and Hypersensitivity that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 168 participants, below the 321-participant average among 15 other Allergy trials with a reported enrollment target (48% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00078195, a Phase 2 study of Allergy and Hypersensitivity, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 3
- Study locations
Study Summary
A series of allergy shots may reduce symptoms of seasonal ragweed allergies. This study will determine whether taking a drug called omalizumab (also known as Xolair) before getting the allergy shots is more effective than allergy shots alone or other treatments, such as prescription antihistamines.
Conditions Studied
Interventions
- BIOLOGICAL omalizumab
- BIOLOGICAL Placebo omalizumab
- BIOLOGICAL Ragweed rush immunotherapy (RIT)
- BIOLOGICAL Placebo rush immunotherapy (RIT)
- BIOLOGICAL Ragweed immunotherapy (IT)
Study Locations (3)
Iowa
- University of Iowa - Iowa City
Nebraska
- Creighton University - Omaha
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078195
The ClinicalTrials.gov registry entry for NCT00078195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 321-participant average among 15 other Allergy trials with a reported enrollment target (48% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Allergy appearing as the primary indexed condition, and to 5 interventions - of which omalizumab is the first listed.
NCT00078195 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Iowa, Nebraska, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00078195 about?
NCT00078195 is a clinical study titled "Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies". A series of allergy shots may reduce symptoms of seasonal ragweed allergies. This study will determine whether taking a drug called omalizumab (also known as Xolair) before getting the allergy shots is more effective than allergy shots alone or other treatments, such as prescription antihistamines.
What is the current status of trial NCT00078195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2003-04. Estimated completion is 2005-05.
What conditions does trial NCT00078195 study?
This clinical trial studies the following conditions: Allergy, Hypersensitivity, Hay Fever, Rhinitis.
What interventions are being tested in trial NCT00078195?
The interventions under investigation include: omalizumab (BIOLOGICAL), Placebo omalizumab (BIOLOGICAL), Ragweed rush immunotherapy (RIT) (BIOLOGICAL), Placebo rush immunotherapy (RIT) (BIOLOGICAL), Ragweed immunotherapy (IT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00078195?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00078195 being conducted?
This trial has 3 study locations across Iowa, Nebraska, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
RECRUITING
-
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
RECRUITING · Phase 4
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Childhood Allergy and the Neonatal Environment
ACTIVE NOT RECRUITING
-
Urban Environmental Factors and Childhood Asthma
COMPLETED
-
Vitamin D, Steroids, and Asthma in African American Youth
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.